靶向C-X-C趋化因子受体4的[¹⁸F]AlF-NOTA-QHY-04 PET/CT在小细胞肺癌分子亚型鉴别中的潜力
这项前瞻性研究纳入35例病理确诊的小细胞肺癌患者,用[¹⁸F]AlF-NOTA-QHY-04 PET/CT参数比较不同分子亚型。SCLC-N亚型原发灶和淋巴结转移灶摄取均显著高于其他三型,鉴别SCLC-N与其他亚型的AUC为原发灶0.868-0.948、淋巴结0.783-0.888。作者初步认为该CXCR4靶向PET/CT可能区分SCLC-N与其他亚型及NE与非NE亚型。
要点
- SCLC-N亚型原发灶和淋巴结转移灶的CXCR4 PET/CT摄取显著高于其他三型(P<0.05)。
- 鉴别SCLC-N与其他亚型的AUC:原发灶0.868-0.948,淋巴结0.783-0.888。
- NE与非NE亚型鉴别AUC:原发灶0.692-0.786,淋巴结0.692-0.815。
核心结论
- 作者初步认为,[¹⁸F]AlF-NOTA-QHY-04 CXCR4靶向PET/CT可能区分SCLC-N与其他分子亚型,以及NE与非NE亚型。
研究设计与样本
- 前瞻性研究纳入35例病理确诊的小细胞肺癌患者,以免疫组化染色分为SCLC-A、SCLC-N、SCLC-P和SCLC-I四个分子亚型,行[¹⁸F]AlF-NOTA-QHY-04 PET/CT并获取SUVmax、SUVmean、SUVpeak及基于SUVmax的肿瘤/正常组织比值(T/NT)。
关键影像表现/征象
- SCLC-N亚型原发灶和淋巴结转移灶的示踪剂摄取均显著高于其他三个亚型(P<0.05)。
- SCLC-N与其他SCLCs合并组比较时,SCLC-N组所有参数均显著更高(P<0.05)。
- 原发灶中NE组SUVmax、SUVmean和T/NTlung显著高于非NE组。
诊断标准与关键数值
- 鉴别SCLC-N与其他SCLCs:原发灶AUC 0.868-0.948,淋巴结转移灶AUC 0.783-0.888。
- 鉴别NE与非NE亚型:原发灶AUC 0.692-0.786,淋巴结转移灶AUC 0.692-0.815。
- 分子亚型构成:SCLC-A n=17、SCLC-N n=6、SCLC-P n=7、SCLC-I n=5。
临床应用与阅片要点
- 阅片时可关注原发灶及淋巴结转移灶的CXCR4靶向摄取水平,SCLC-N亚型摄取更高。
- 作者认为该显像可能用于辅助区分SCLC-N与其他亚型以及NE与非NE亚型。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: Molecular subtyping of small-cell lung cancer (SCLC) has major implications for prognostic relevance and treatment guidance. This study aimed to explore the feasibility of a novel tracer targeting C-X-C-chemokine-receptor-type-4 (CXCR4) for distinguishing different SCLC subtypes.
MATERIALS AND METHODS: Thirty-five patients with pathologically confirmed SCLC were enrolled in this prospective study. Immunohistochemical staining was performed to classify the molecular subtypes into SCLC-A, SCLC-N, SCLC-P, and SCLC-I. [¹⁸F]AlF-NOTA-QHY-04 PET/CT parameters were obtained, including the maximum, mean, and peak standard uptake values (SUVmax, SUVmean, and SUVpeak, respectively) and the ratios of tumors (T) and normal tissues (NT) based on the SUVmax (T/NT). These parameters were compared among the molecular subtypes. A receiver operating characteristic (ROC) curve was used to analyze the performance of the parameters for distinguishing SCLC-N from other subtypes and neuroendocrine (NE) subtypes (SCLC-A and SCLC-N) from non-NE subtypes (SCLC-P and SCLC-I).
RESULTS: The molecular subtypes were SCLC-A (n = 17), SCLC-N (n = 6), SCLC-P (n = 7), and SCLC-I (n = 5). The SCLC-N subtype exhibited significantly higher uptake in both primary tumors and lymph node metastases than the other three subtypes (P < 0.05). When SCLC-N was compared with the other three subtypes combined (referred to as "other SCLCs"), all parameters were significantly higher in the SCLC-N group (P < 0.05). ROC analysis showed that these parameters had high accuracy in distinguishing SCLC-N from other SCLCs (area under ROC curve: 0.868-0.948 for primary tumors and 0.783-0.888 for lymph node metastases). Compared with the non-NE group, the SUVmax, SUVmean, and T/NTlung were significantly higher in the NE group for primary tumors. ROC analysis showed moderate accuracy in distinguishing between the NE and non-NE groups (ROC area: 0.692-0.786 for primary tumors and 0.692-0.815 for lymph node metastases).
CONCLUSION: Our preliminary findings indicate that CXCR4-directed PET/CT imaging using [¹⁸F]AlF-NOTA-QHY-04 may differentiate between SCLC-N and other molecular subtypes and between NE and non-NE subtypes of SCLC.
引用
- Luo Y, Cheng K, Liu J, et al. Potential of C-X-C-Chemokine-Receptor-Type-4-Directed PET/CT Using [¹⁸F]AlF-NOTA-QHY-04 in Identifying Molecular Subtypes of Small Cell Lung Cancer. Korean J Radiol. 2025. PMID: 40432263. doi:10.3348/kjr.2024.1266
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。